——
Level — · Streak —
— XP
Mastery—weighted
Quizzes 30d—last 30 days
Cert progress—active level
Rank—global
Loading...
The page behind this dialog is live. Create a free account or sign in and you'll land right back on it.
Triangulating from multiple angles
No single valuation method is perfect. Professional analysts triangulate across multiple methods: relative multiples (P/E, EV/EBITDA, P/FCF), absolute valuation (DCF), and sanity checks against historical ranges and peer-group context. When all methods agree the company is cheap, confidence is high; when they agree it's expensive, conviction is also high. When they disagree, the disagreement itself is information about which assumptions matter and where the analysis needs more work. Triangulation is the discipline that separates rigorous fundamental analysis from single-metric mistakes.
The valuation triangle has three corners. (1) Relative valuation: how does the company's P/E, EV/EBITDA, P/FCF compare to peers and to its own historical range? Is current pricing in the high, middle, or low end of where the market has historically valued similar businesses or this same business? (2) Absolute valuation: DCF based on fundamentals — what is the company actually worth as a function of expected future cash flows discounted at appropriate WACC? (3) Sanity checks: does the implied growth rate in the multiple make sense? Is the FCF yield attractive relative to bonds? Would an acquirer pay this price (private-market value)? The three corners reinforce each other when consistent. When inconsistent, ask which corner is wrong before assuming the cheapest one is right.
Use these as rough guides, not absolute thresholds. Deep-value cyclicals trade at 8-12x P/E (low expectations or high cycle risk). Average-quality businesses trade at the S&P 500 long-run average of 15-20x. Quality growers (MSFT, V, COST) trade at 25-35x because durable moats + steady growth justify premium multiples. Exceptional compounders in their growth phase (NVIDIA in the AI cycle) trade at 35-50x. Hypergrowth and pre-profit names (early SaaS, biotech) trade at 50-100x+ because they're priced for future earnings rather than current. Within each band, valuation discipline still matters — the worst-case scenarios are companies trading like one band when fundamentals support a lower band.
The is what to apply before every investment decision. Question 1: Is this a great business? Run the M4 qualitative scorecard and the m5 financial-ratio workflow. Question 2: Is it fairly or cheaply priced? Triangulate across multiples and DCF; check against historical ranges and peer set. Question 3: Why does this opportunity exist? If a great business is trading at a fair or cheap price, what's the market missing? Time-horizon arbitrage (the market is too short-term)? Information asymmetry (a small-cap underfollowed name)? Cyclical mispricing (cyclical at trough earnings looks expensive on trailing P/E)? Sentiment overshooting (oversold during macro panic)? If you can articulate the answer convincingly, the investment case is strong. If you can't, you may be missing something the market sees.
In 1972, Berkshire Hathaway acquired See's Candies for \$25M (Buffett's most-discussed early acquisition). Annual sales at the time were ~\$30M and pre-tax earnings were ~\$5M, so the multiple was 5x pre-tax earnings — already cheap by 1972 standards. But the more important fact: See's required almost no capital reinvestment to grow (asset-light brand, modest plant capacity, repeat-purchase customer base). Over the next 40+ years, See's distributed multi-billion dollars in cumulative cash to Berkshire on the original \$25M investment — a return of well over 100x in cumulative cash returns. Buffett has called See's the 'prototype of a dream business' precisely because the combination of high ROIC, low reinvestment need, and durable brand created a multi-decade compounding machine. The margin of safety in 1972 was the combination of low purchase multiple AND undervalued business quality (the market was treating See's as a normal candy company; Buffett recognized it as a high-ROIC franchise). When triangulation across relative, absolute, and qualitative dimensions all agree, the investment thesis is compounding. Source: Berkshire Hathaway annual letters; Buffett's discussions of See's Candies in the 1991, 1996, and 2014 letters specifically.
The Valuation tab presents all major multiples and a DCF model side-by-side, with peer-group comparison and 10-year historical context for each metric. The Insights tab integrates the qualitative scorecard from m4 with the valuation outputs to support multi-dimensional analysis. The /screener page lets you filter by combinations of valuation and quality criteria — useful for finding rare combinations of high quality + reasonable valuation. The Filings tab provides source documents for any of the inputs you want to verify or adjust.
First: cherry-picking the most favorable multiple. If P/E is low, EV/EBITDA is low, and P/FCF is low, all three convergent: cheap. If P/E is low but P/FCF is high (because of FCF/income divergence — a forensic flag), don't pick P/E and ignore P/FCF. Second: anchoring DCF to multiples. Many analysts inadvertently set DCF inputs to produce intrinsic values matching current market price. Test by computing DCF with conservative inputs first and seeing if intrinsic value is below current price; if yes, the conservative DCF disagrees with the multiples and the disagreement matters. Third: missing quality. Cheap stocks of declining businesses are cheap for a reason — running the M4 quality scorecard before forming a valuation thesis filters out most value traps. The combination 'cheap multiples + low quality' is the single most expensive analytical pattern in fundamental investing.
What we want from a great investment is the kind of business where you would be comfortable holding it for the long run — and where the price you pay leaves enough margin of safety that even if your analysis turns out to be partly wrong, you still don't lose money. The combination — wonderful business, fair price, margin of safety — is what produces extraordinary long-term results.